CellFE Biotech marks continued growth with new CBO hire

CellFE Biotech, a venture-backed startup focused on microfluidics-based platforms for cell and gene engineering, has announced the appointment of Kevin Gutshall as Chief Business Officer.

Gutshall’s background in biotech-focused business development promises to bring a wealth of industry expertise to the CellFE executive team. Gutshall most recently served as the VP of Strategy and Corporate Development on the senior leadership team at MaxCyte, where he led the development of the firm’s growth strategy, including strategic partnerships and M&A.

He has also held positions as Director of Corporate Development at MilliporeSigma, Head of BD at Sigma-Aldrich, and Director of Marketing at ThermoFisher Scientific, demonstrating over 20 years of industry experience in business development and marketing.

“We are excited to welcome Kevin to our executive leadership team. Kevin will drive our sales marketing and business development strategy and execution, as we continue to accelerate growth of CellFE’s cell therapy manufacturing platform,” said Alla Zamarayeva, CEO of CellFE.

The appointment of a new CBO marks a continuing push for growth at CellFE, given the rapidly increasing demand for novel technologies for scalable and cost-effective manufacturing personalized cell and gene therapies.

About CellFE

CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally to enable low-cost, high-yield manufacturing of cell and gene therapies at scale. 

CellFE’s executive team is composed of members who bring strong expertise in the theoretical and practical aspects of the technology, as well as experience in leadership and business operations. CellFE’s research and development efforts are led by world-class scientists who are passionate about using microfluidics to transform how cell and gene therapies are manufactured.